Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

Background Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET). Methods This is a pooled analysis of two multicentre, randomised non-comparative phase 2 clinical trials evaluating neoadjuvant anastrozole and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2020-03, Vol.122 (6), p.759-765
Hauptverfasser:	Lerebours, Florence, Pulido, Marina, Fourme, Emmanuelle, Debled, Marc, Becette, Véronique, Bonnefoi, Hervé, Rivera, Sofia, MacGrogan, Gaetan, Mouret-Reynier, Marie-Ange, de Lara, Christine Tunon, Pierga, Jean-Yves, Breton-Callu, Christel, Venat-Bouvet, Laurence, Mathoulin-Pélissier, Simone, de la Motte rouge, Thibault, Dalenc, Florence, Sigal, Brigitte, Bachelot, Thomas, Lemonnier, Jérôme, Quenel-Tueux, Nathalie
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1347 692/499 692/699/67/1347 Aged Anastrozole Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Cancer Research Cancer therapies Chemotherapy Clinical trials Drug Resistance Endocrine therapy Epidemiology ErbB-2 protein Female Fulvestrant Humans Life Sciences Medical prognosis Molecular Medicine Multivariate analysis Neoadjuvant Therapy - methods Oncology Patients Post-menopause Prognosis Surgery Survival Survival Analysis Time Factors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!